Clinical Outcomes of Later‐Generation <scp>EGFR</scp> ‐ <scp>TKIs</scp> for Uncommon <scp>EGFR</scp> Mutations in <scp>NSCLC</scp> : A Multicenter Real‐World Study
Lisa Shigematsu(Keio University), Yoshitaka Oyamada(Keio University), Kenzo Soejima(Keio University), Shigenari Nukaga(Tokyo Medical Center), Tetsuo Tani(Keio University), Shinnosuke Ikemura(Keio University), Keiko Ohgino(Keio University), Fumio Sakamaki(Keio University), Hideki Terai(Kitasato Institute Hospital), Taro Shinozaki(Keio University), Koichi Fukunaga(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Katsuhiko Naoki(Broad Institute), Takashi Sato(Kitasato University), Kohei Horiuchi(Icahn School of Medicine at Mount Sinai), Koichi Sayama(Beth Israel Deaconess Medical Center)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101